Efficacy and safety of immunotherapy combined with antiangiogenesis agents and temozolomide in neuroendocrine carcinoma

#4374

Introduction: Platinum-based doublet chemotherapy is the standard first-line treatment, without standard treatment for second-line or subsequent systemic therapy for recurrent or progressive advanced neuroendocrine cancer (NEC).

Aim(s): To evaluate the development of more effective treatment strategies in patients with NEC.

Materials and methods: Retrospective study of 12 patients with recurrent or progressive advanced NEC at department of Oncology, the First Affiliated Hospital of Zhengzhou University, between 9/2023 and 10/2024 treated with immunotherapy combined with and antiangiogenesis agents and temozolomide.

Conference:

Presenting Author:

Authors: Li X, Yang M, Fan Q, Song L,

Keywords: Neuroendocrine carcinoma, Immunotherapy, Antiangiogenesis agents, Temozolomide,